Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | LDHA | P00338 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11377804 | 0.86 | MAPT (0.43) | MAPTCYP1A2ALDH1A1 | |
| SCHEMBL4068945 | 0.86 | MAPT (0.43) | MAPTSMN1; SMN2ALDH1A1KMT2ARAB9A | |
| SCHEMBL538763 | 0.86 | MAPT (0.52) | MAPTALDH1A1KMT2AMMP8 | |
| SCHEMBL1155256 | 0.85 | POLB (0.44) | MAPTCYP1A2KMT2A | |
| SCHEMBL4281827 | 0.85 | MAPT (0.43) | MAPTCYP1A2KDM4ESMN1; SMN2ALDH1A1 | |
| Methane SCHEMBL11382581 | 0.84 | MAPT (0.51) | MAPTALDH1A1KMT2AMMP8 | |
| SCHEMBL290365 | 0.83 | ALDH1A1 (0.43) | MAPTKDM4ESMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL11623149 | 0.82 | MAPT (0.41) | MAPTALDH1A1RAB9AALOX5 | |
| SCHEMBL999787 | 0.81 | MMP8 (0.55) | MAPTCYP1A2ALDH1A1KMT2AMMP8 | |
| SCHEMBL11489097 | 0.80 | MEN1 (0.38) | MAPTKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768975-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
| WO-2006000912-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | TPH2, HTR1A, TPH1 | MAPT 1058/4885CYP1A2 45/4885FPR2 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.